In a report released on July 29, Puneet Souda from Leerink Partners maintained a Buy rating on Repligen, with a price target of $200.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Puneet Souda has given his Buy rating due to a combination of factors that highlight Repligen’s strong position in the bioprocessing market. The company demonstrated impressive growth, with orders increasing by over 20% year-over-year and consistent quarter-over-quarter growth. This was driven by robust performance across various product categories, geographies, and end markets, particularly in the pharmaceutical and CDMO sectors.
Additionally, despite some concerns about gene therapy exposure and competition, management’s commentary in the second quarter helped alleviate these worries. The company’s ability to maintain broad-based order strength and capitalize on opportunities in the ATF segment suggests that recent controversies are overstated. Overall, Repligen’s momentum in order recovery and growth prospects make it a compelling investment opportunity, justifying the Buy rating.
Souda covers the Healthcare sector, focusing on stocks such as Quanterix, Bruker, and Exact Sciences. According to TipRanks, Souda has an average return of -9.6% and a 31.94% success rate on recommended stocks.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $150.00 price target.